Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer

Rhea-AI Summary

Oncology Pharma (OTC PINK:ONPH) has signed a license agreement with Regen BioPharma for mRNA intellectual property aimed at developing therapies for pancreatic cancer. This agreement enhances ONPH's intellectual property portfolio and demonstrates its commitment to the cancer therapy market. The company believes this milestone reflects its goals in brand development. However, the press release mentions potential risks, such as negative cash flows and the need for additional funding, which could impact the company’s operations and financial stability.

Positive

• Signed a license agreement with Regen BioPharma for mRNA technology.
• Expansion of intellectual property portfolio for pancreatic cancer therapy.
• Commitment to developing quality cancer therapies.

Negative

• Current negative operating cash flows.
• Need for additional funding could be highly dilutive.
• Risks related to licensing arrangements and potential legal proceedings.

SAN FRANCISCO, CA / ACCESSWIRE / April 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) signed a license agreement with Regen BioPharma Inc. for intellectual property pertaining to mRNA to be used in developing a therapy for treating pancreatic cancer. This license agreement expands the Company's portfolio of intellectual property that It plans to develop for niche biotechnology markets.

Oncology Pharma issued a statement "We are looking to expand our presence in the cancer therapy market. This showcases our commitment to developing quality therapies to make patients lives better."

A spokesperson for the Company said the company believes this is a major milestone for the company and is evidence of it achieving its goals in brand development.

ABOUT ONCOLOGY PHARMA, INC.

ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.

FORWARD LOOKING STATEMENTS

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.

CONTACTS:

For additional Information, please contact the Oncology Pharma at:

One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
Email: info@oncology-pharma.com
Website: www.oncology-pharma.com

SOURCE: Oncology Pharma Inc.

View source version on accesswire.com:
https://www.accesswire.com/639366/Oncology-Pharma-Signs-License-Agreement-for-mRNA-Intellectual-Property-As-It-Reveals-Strategic-Plans-for-Treating-Pancreatic-Cancer

FAQ

What is the recent agreement signed by Oncology Pharma (ONPH)?

Oncology Pharma signed a license agreement with Regen BioPharma for mRNA intellectual property to develop therapies for pancreatic cancer.

How does the license agreement impact Oncology Pharma's business?

The agreement enhances Oncology Pharma's intellectual property portfolio, positioning it better in the cancer therapy market.

What are the financial risks mentioned in the Oncology Pharma press release?

The press release identifies risks like negative cash flows, the need for additional funding, and uncertainties related to licensing arrangements.

What are Oncology Pharma's plans for cancer therapy?

Oncology Pharma aims to expand its presence in the cancer therapy market with a focus on developing quality therapies.